Last updated June 12, 2026
Key finding
Significant between-group differences in favour of iGlarLixi were observed in body weight: −4.19 (−5.95, −2.43) kg.
This study evaluated the effectiveness of insulin glargine-lixisenatide fixed-ratio combination (iGlarLixi) in individuals with type 2 diabetes. It found significant improvements in body weight, BMI, and insulin dosage compared to multiple daily injections (MDI).
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effectiveness of insulin glargine-lixisenatide fixed-ratio combination (iGlarLixi) in individuals with type 2 diabetes. It found significant improvements in body weight, BMI, and insulin dosage compared to multiple daily injections (MDI).
These findings are clinically significant as they suggest that the iGlarLixi combination therapy may offer a more effective and convenient treatment option for managing type 2 diabetes, potentially leading to better patient adherence and improved health outcomes.
The study was open-label, which may introduce bias. The sample size and demographic characteristics were not detailed. Long-term effects of iGlarLixi were not assessed.
Published in
Publication details and source links for this paper.
Peter N, Lenka T, Ivana L, et al. Insulin therapy simplification from multiple daily injections to once-daily iGlarLixi in people with type 2 diabetes: a phase IV randomized controlled trial. Diabetes, Obesity & Metabolism. 2025. doi:10.1111/dom.70362
iGlarLixi reduced body weight by −4.19 kg compared to MDI.
iGlarLixi decreased BMI by −1.49 kg/m² compared to MDI.
iGlarLixi reduced total daily insulin dose by −28.57 IU compared to MDI.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Body Mass Index (BMI) change, Glycemia risk index, HbA1c, and 3 more.
This study contributes evidence to
Primary intervention
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
6
Evidence pairs
496
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Body Mass Index (BMI) change
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Body Mass Index (BMI) change
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Glycemia risk index
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Glycemia risk index
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → HbA1c
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → HbA1c
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Time above 13.9 mmol/L
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Time above 13.9 mmol/L
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Total daily insulin dose
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Total daily insulin dose
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Weight change
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Weight change
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and Insulin Resistance.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
3 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies appears to improve Insulin Resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Total daily insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve CGM Time in Range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Glycemia risk index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Time above 13.9 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Weight change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
